Official batch control of influenza vaccines: Is it still useful?
| Autor: | Michael Pfleiderer, Evelyne Kretzschmar, Heide Muckenfuss |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Quality Control
0301 basic medicine 040301 veterinary sciences Influenza vaccine Paul ehrlich institute media_common.quotation_subject Control (management) Governmental agency Context (language use) Vaccine Production 0403 veterinary science 03 medical and health sciences Government Agencies Germany Product Surveillance Postmarketing Humans media_common.cataloged_instance Quality (business) Marketing European union media_common General Veterinary General Immunology and Microbiology Vaccination Public Health Environmental and Occupational Health 04 agricultural and veterinary sciences 030104 developmental biology Infectious Diseases Influenza Vaccines Molecular Medicine Business Laboratories |
| Zdroj: | Vaccine. 36:2364-2370 |
| ISSN: | 0264-410X |
| Popis: | Introduction The governmental quality control of human vaccines is a long established tradition in many European countries. In Germany, vaccines have been controlled by a governmental agency since 1935. In the beginning, vaccine production and control was a purely national activity. However, that changed fundamentally in 1994 when the so-called Official Control Authority Batch Release Network (OCABR) was implemented shortly after the establishment of the European Union. Today, Official Medicinal Control Laboratories (OMCLs) are part of the European OCABR Network. In many European countries, OMCLs experimentally test every batch of human vaccines before they enter the market. We wanted to gain insights into the benefits of batch release by the Network and address the question whether batch release is still useful. This question was investigated in the context of influenza vaccines. Methods Notifications on influenza vaccines circulated from 2006 to 2016 within the OCABR network were compiled and organized into 32 cases. The impact of these findings was evaluated, and the communication pathways between companies and respective European control laboratories were examined. Results Approximately 5850 batches were tested by the OMCL network between 2006 and 2016. Among these, notifications belonging to 32 cases were observed. The predominant proportion of the circulated notifications related to manufacturing issues. In most cases, the manufacturer itself had withdrawn the batches before they entered the market. However, in three cases, batches of insufficient quality were detected by the respective European Control Laboratory leading to withdrawal of 13 batches. Conclusion 13 batches which did not meet the specifications of influenza vaccine were detected by the OMCL network between 2006 and 2016 which would not have been identified by the manufacturer. This demonstrates the impact of governmental batch release. Together with the intrinsic values of the OCABR system and keeping in mind that vaccines are given to healthy often young individuals, governmental batch release of influenza vaccines is still justified. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect